24. Review: Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, et al. (2017) The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med.
25. Review: Reuter A, Tisile P, von Delft D, Cox H, Cox V, et al. (2017) The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis 21: 1114-1126.
26.Viewpoint: Burki TK (2017) The uphill battle to find new TB treatments. Lancet Respir Med.
27. Viewpoint: Cox H, Reuter A, Furin J, Seddon J (2017) Prevention of hearing loss in patients with multidrug-resistant tuberculosis. Lancet 390: 934.
28. Original Research: Mohr E, Daniels J, Muller O, Furin J, Chabalala B, et al. (2017) Missed opportunities for earlier diagnosis of rifampicin-resistant tuberculosis despite access to Xpert((R)) MTB/RIF. Int J Tuberc Lung Dis 21: 1100-1105.
29. Original Research: Aw B, Ade S, Hinderaker SG, Dlamini N, Takarinda KC, et al. (2017) Childhood tuberculosis in Mauritania, 2010-2015: diagnosis and outcomes in Nouakchott and the rest of the country. Public Health Action 7: 199-205. (SORT-IT course participant)
30. Original Research: Choun K, Achanta S, Naik B, Tripathy JP, Thai S, et al. (2017) Using mobile phones to ensure that referred tuberculosis patients reach their treatment facilities: a call that makes a difference. BMC Health Serv Res 17: 575. (SORT-IT course participant)
31. Original Research: Gadoev J, Asadov D, Harries AD, Parpieva N, Tayler-Smith K, et al. (2017) Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan. PLoS One 12: e0176473. (SORT-IT course participant)
32. Original Research: Goncharova O, Denisiuk O, Zachariah R, Davtyan K, Nabirova D, et al. (2017) Tuberculosis among migrants in Bishkek, the capital of the Kyrgyz Republic. Public Health Action 7: 218-223. (SORT-IT course participant)
33. Original Research: Han WW, Saw S, Isaakidis P, Khogali M, Reid A, et al. (2017) Different challenges, different approaches and related expenditures of community-based tuberculosis activities by international non-governmental organizations in Myanmar. Infect Dis Poverty 6: 59. (SORT-IT course participant)
34. Original Research: Maung HM, Saw S, Isaakidis P, Khogali M, Reid A, et al. (2017) The contribution of a non-governmental organisation's Community Based Tuberculosis Care Programme to case finding in Myanmar: trend over time. Infect Dis Poverty 6: 51. (SORT-IT course participant)
35. Original Research: Myint O, Saw S, Isaakidis P, Khogali M, Reid A, et al. (2017) Active case-finding for tuberculosis by mobile teams in Myanmar: yield and treatment outcomes. Infect Dis Poverty 6: 77. (SORT-IT course participant)
36. Original Research: Ncube RT, Takarinda KC, Zishiri C, van den Boogaard W, Mlilo N, et al. (2017) Age-stratified tuberculosis treatment outcomes in Zimbabwe: are we paying attention to the most vulnerable? Public Health Action 7: 212-217. (SORT-IT course participant)
37. Original Research: Nwe TT, Saw S, Le Win L, Mon MM, van Griensven J, et al. (2017) Engagement of public and private medical facilities in tuberculosis care in Myanmar: contributions and trends over an eight-year period. Infect Dis Poverty 6: 123. (SORT-IT course participant)
38. Original Research: Soe KT, Saw S, van Griensven J, Zhou S, Win L, et al. (2017) International non-governmental organizations' provision of community-based tuberculosis care for hard-to-reach populations in Myanmar, 2013-2014. Infect Dis Poverty 6: 69. (SORT-IT course participant)